Securities code: 603222 securities abbreviation: Chimin Health Management Co.Ltd(603222) Announcement No.: 2022-006
Chimin Health Management Co.Ltd(603222)
Correction announcement of 2021 annual performance forecast
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
Due to the negligence of the staff, Chimin Health Management Co.Ltd(603222) (hereinafter referred to as “the company”) was registered at the Shanghai Stock Exchange (www.sse. Com. CN.) on January 18, 2022 The contents (monetary unit) of the Chimin Health Management Co.Ltd(603222) 2021 annual performance forecast are disclosed incorrectly, which are corrected as follows:
After correction
3、 The performance of this period has changed (I) Jumin, a wholly-owned subsidiary of the company (I) Jumin, a wholly-owned subsidiary of the company, is vivid. The safety syringe (needle) products of Biotechnology Co., Ltd. Safety Injection Technology Co., Ltd. have been sold throughout the year (needle) products have been sold about 600 million throughout the year, and the net profit is about 100 million, The net profit was about 152.2 billion yuan, an increase of yuan over the previous year and a large increase over the previous year; Large degree of;
In addition to the above matters, other contents of the original announcement remain unchanged. We apologize for the inconvenience caused to investors by our negligence.
It is hereby announced.
Chimin Health Management Co.Ltd(603222) board of directors January 18, 2022
